Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCPD5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $16,584.13 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. The delivery order, issued on December 3, 2025, with an ultimate completion date of December 24, 2025, was made without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that enables the agency to procure pharmaceutical products to support Department of Defense healthcare operations globally.
DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a critical supplier within the military pharmaceutical supply chain, with a robust product portfolio encompassing branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. The company's established performance on numerous delivery orders across multiple therapeutic categories and its position as a regional prime vendor contractor under the PPV-G GEN V program positions it as a key provider of the diverse and specialized pharmaceutical requirements necessary to support military healthcare facilities worldwide. The underlying indefinite delivery contract, valued at $499,999,999 with an ultimate completion date of December 31, 2036, includes a 30-month base period and three 30-month option periods.
Quick answers
Who was awarded contract SPE2DR26FCPD5?
SPE2DR26FCPD5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26FCPD5 worth?
The government has obligated $16,584 on SPE2DR26FCPD5.
Is contract SPE2DR26FCPD5 an order under another contract?
Yes. SPE2DR26FCPD5 is a delivery order under SPE2DR25D9131, an indefinite delivery contract.
Was contract SPE2DR26FCPD5 competed?
The extent of competition for SPE2DR26FCPD5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award